MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On December 29, 2017, Medovex Corp., a Nevada corporation (the “Company”) issued a press release (the “Release”) announcing that it has elected to voluntarily convert its previously submitted Investigational Device Exemption to a Pre-Submission with the U.S. Food and Drug Administration for its DenerveX device. A copy of the Release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.
The information contained in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information contained in this Current Report on Form 8-K constitutes material investor information that is not otherwise publicly available.
The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release dated December 29, 2017 |
Medovex Corp. ExhibitEX-99.1 2 ex99-1.htm Medovex Corporation Converts IDE Submission to a Pre-Submission with Food and Drug Administration for its DenerveX System Adds Six New Independent Sales Agents in Germany and Collecting Patient Data for Anticipated Filing of Scientific Post Procedural Outcomes of Patients Abstract ATLANTA,…To view the full exhibit click here
